Norbixin

DB15201ExperimentalSmall molecule

Norbixin is under investigation in clinical trial NCT03820245 (Effect of Short-term Annatto Carotenoids Supplementation on Oxidative Stress Status in Healthy Individuals).

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor gamma, Tyrosinase, and Human Retinoid X Receptors (RXRs)
Curator reviewed
Formula / weight: C₂₄H₂₈O₄ · 380.484 g/mol (avg)

Resolves to

Compound

UNIIE8M59E17AICAS542-40-5ChEMBLCHEMBL1602127ChEBI7623KEGGC08608

Structure

InChIKeyZVKOASAVGLETCT-UOGKPENDSA-NSMILESC\C(\C=C\C=C(/C)\C=C\C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C(O)=O

Targets

P37231PPARGP14679TYR

What you can answer from here — as of July 08, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Norbixin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account